Skip to main content
Bora logo

Bora — Investor Relations & Filings

Ticker · 6472 ISIN · TW0006472004 LEI · 254900MK7O5C2UX1SY03 TW Manufacturing
Open in API
Filings indexed 82 across all filing types
Latest filing 2026-06-11 Director's Dealing
Country TW Taiwan
Listing TW 6472

About Bora

https://bora-corp.com/

Bora Pharmaceuticals Co., Ltd. is a global pharmaceutical service provider that operates through a "dual-engine" business model, integrating comprehensive Contract Development and Manufacturing Organization (CDMO) services with the development and commercialization of specialty pharmaceuticals. The company provides end-to-end solutions ranging from formulation development and clinical trial materials to large-scale commercial manufacturing. Its technical capabilities encompass a diverse array of dosage forms, including oral solids, liquids, and semi-solids. With a manufacturing footprint spanning multiple continents, the company serves global markets by leveraging advanced production technologies and rigorous quality management systems. Bora Pharmaceuticals focuses on strategic growth through acquisitions and partnerships, aiming to enhance manufacturing efficiency and accelerate the delivery of complex therapeutic treatments to patients worldwide.

Recent filings

Filing Released Lang Actions
115年6月10日內部人設質解質
Director's Dealing Classification · 95% confidence The document is an insider share pledge announcement from the company’s chairman (a director-level insider) listing pledged and released share quantities, dates, and pledgee. This constitutes a personal share transaction by a company director (insider dealing). Therefore, it falls under Director’s Dealing (Code: DIRS).
2026-06-11 Chinese
代子公司TWi Pharmaceuticals USA, Inc.依「公開 發行公司資金貸與及背書保證處理準則」第二十二條第一項 第三款公告申報
Capital/Financing Update Classification · 85% confidence The document is an official announcement on the public information platform detailing a subsidiary’s loan (資金貸與) to another company under regulatory guidelines. It outlines financing terms, amounts, purposes, and balances. This constitutes an update on the company’s financing activities rather than a full financial report, board change, earnings release, or share transaction. Therefore it fits the Capital/Financing Update category.
2026-06-10 Chinese
公司治理組織架構
Governance Information Classification · 87% confidence The document is a static table from Taiwan’s Market Observation Post System detailing the company’s board composition, independent director seats, committee establishments (audit, remuneration), legal advisors, and procedures for shareholder suggestions or disputes. It outlines the internal governance structure rather than announcing a specific change or election result. This matches the Governance Information category (CGR).
2026-06-10 Chinese
本公司受邀參加Goldman Sachs舉辦之GS China Healthcare Corporate Day Jun 2026
Regulatory Filings Classification · 82% confidence The document is a brief regulatory announcement on Taiwan’s Market Observation Post System (MOPS) providing details of an upcoming institutional investor presentation (“法人說明會”) at a Goldman Sachs corporate day. It does not itself contain financial data or presentation slides, nor is it a management discussion or transcript. This is a regulatory notice of an IR event, best categorized as a miscellaneous regulatory filing.
2026-06-09 Chinese
115年06月法人說明會簡報 — 647220260311E004.pdf
Investor Presentation Classification · 92% confidence The document is a slide deck presenting Bora Pharmaceuticals’ Q4 and full-year FY25 financial results, forward-looking statements, strategic initiatives, and operational highlights. It is not a simple earnings press release (ER) or regulatory certification; it is a detailed investor-facing presentation covering financials, strategy, market position, and outlook. Therefore it fits the Investor Presentation category.
2026-06-09 English
115年06月法人說明會簡報 — 647220260311M004.pdf
Investor Presentation Classification · 88% confidence The document is a slide deck titled “FY25 Earnings Release” with forward-looking statements, detailed financial tables (P&L by quarter and year), strategic milestones, business segment breakdowns, and capacity expansion plans. It is structured as an investor presentation rather than a simple press release or full annual report. Therefore, it is best classified as an Investor Presentation (IP).
2026-06-09 English

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.